Abbvie faces multiple Humira antitrust suits

04-04-2019

Abbvie faces multiple Humira antitrust suits

casimiropt / Shutterstock.com

AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira (adalimumab).


AbbVie, Humira, antitrust, competition, licensing deals, patent thickets, Pfizer, Sandoz, Mylan, biosimilars

LSIPR